Andrew Yee

2 weeks ago | cancernetwork.com | Hans Lee |Andrew Yee

June 13, 2025By Panelists discuss how recent data support the use of quadruplet regimens—including anti-CD38 antibodies—even in older or moderately frail patients with newly diagnosed multiple myeloma, shifting treatment decisions from transplant eligibility to functional status and depth of response.

2 weeks ago | cancernetwork.com | Hans Lee |Andrew Yee

June 13, 2025By Panelists discuss how subcutaneous anti-CD38 monoclonal antibodies are reshaping frontline multiple myeloma treatment by improving efficacy, tolerability, and patient convenience across both transplant-eligible and ineligible populations. Recent advancements in the treatment of newly diagnosed multiple myeloma have significantly reshaped clinical strategies, particularly in both transplant-eligible and transplant-ineligible populations.

Jul 31, 2024 | lifewithoutandy.com | Andrew Yee

Anna Lunoe image by Billy Zammit //Boiler Room is set to make history in Sydney this December with its biggest-ever line-up. Hosted at the Munro Warehouse, Sydney Showground, on December 7th, the event will feature an impressive roster of 17 top-tier local and international DJs.The event will showcase diverse musical styles across two stages, each offering a distinct atmosphere.

Jul 7, 2024 | nature.com | Andrew Yee

Therapies targeting BCMA are transforming the care of multiple myeloma, with unprecedented depth and durability of responses in patients with heavily treated disease. The field is moving rapidly, especially with the recent approval of anti-BCMA CAR T-cells in as early as one prior line of therapy with ciltacabtagene autoleucel (cilta-cel) and two prior lines of therapy with idecabtagene vicleucel.